Simplify the Comlex: Innovative Solutions for FXIa Removal from Cobetter

A critical finding has reshaped the blood products industry: residual FXIa (Factor XIa) has been identified as a root cause of thromboembolic events associated with certain IVIG products. During IVIG manufacturing, several coagulation factors—including Factors II, VII, IX, X, and FXIa—may remain in intermediate fractions. Among these, FXIa poses the greatest risk due to its potent procoagulant activity, which can induce pathological coagulation even at trace concentrations. This realization has made effective FXIa removal a core requirement for the blood products industry in safeguarding product safety. 

What is FXIa? 

FXIa is the active serine protease derived from coagulation Factor XI (FXI) through proteolytic cleavage. FXI itself is synthesized in the liver. Genetically, its gene arose from a duplication of the plasma prekallikrein (PK) gene and later diverged to acquire specialized coagulation functions. Structurally, FXI is unique among coagulation proteases: it is the only serum protease that exists as a homodimer, composed of two identical 80 kDa subunits linked by a disulfide bond between Cys321 residues. 

The activation of FXI to FXIa requires the cleavage of the Arg369–Ile370 peptide bond in each subunit. 

Zymogen State: 

FXI exists as a homodimer in its zymogen form. Each subunit comprises four N-terminal Apple domains and one C-terminal catalytic domain. At this stage, the catalytic domain remains in an inactive conformation, with the substrate-binding pocket occupied by its own amino acid sequence. 

After Activation: 

Upon proteolytic cleavage, a disulfide-linked two-chain molecule is formed. The N-terminal heavy chain, containing the Apple domains, mediates recognition and binding of cofactors and substrates. Meanwhile, the C-terminal light chain, which houses the catalytic triad, undergoes a conformational change to create a functional active site, thereby acquiring serine protease activity. 

Clinical Impact of FXIa 

Once generated, FXIa acts on multiple substrates beyond its primary target FIX, forming a complex regulatory network with three major clinical consequences: 

• Coagulation function: Efficiently activates coagulation Factor IX (FIX) to FIXa, amplifying the coagulation cascade. 
• Pro-inflammatory effect: Activates FXII and prekallikrein (PK), triggering bradykinin release, which mediates increased vascular permeability and inflammation.
• Anti-fibrinolytic effect: Through massive thrombin generation, it activates thrombin-activatable fibrinolysis inhibitor (TAFI), protecting fibrin clots from premature dissolution. 

Process Methods for FXIa Removal in IVIG Manufacturing 

Caprylic Acid Precipitation 

Principle 

This method exploits the selective precipitation of high-molecular-weight impurity proteins, including FXIa, by caprylic acid under mildly acidic conditions, while IgG remains largely soluble in the supernatant. 

Strengths 

1. Outstanding efficiency: A single precipitation step can remove ≥99.9% of FXIa activity. 
2. Good cost-effectiveness: The reagent is inexpensive and no complex chromatography equipment is required. 
3. Broad-spectrum purification: It simultaneously removes multiple hydrophobic contaminant proteins and some enveloped viruses. 

Weaknesses 

1. Condition-sensitive: Requires meticulous control of pH, temperature, reagent concentration, and incubation duration 
2. Limited specificity: Some IgG may co-precipitate, leading to yield loss. 
3. Insufficient as a standalone step: It may not consistently reduce residual FXIa to the most rigorous purity specifications, necessitating subsequent polishing steps. 

Cation Exchange Chromatography (CEX) 

Principle 

This method relies on surface charge differences under specific buffer conditions. IgG is retained on the cation exchange resin, while FXI and FXIa either pass through the column or are eluted preferentially. 

Strengths 

1. Robust clearance: Even at FXIa spike concentrations 158 times the normal level, removal exceeds 99%, with residual activity falling below the detection limit. 
2. Dual-component removal: FXI and FXIa are cleared simultaneously in a single step, reducing the risk of reactivation. 
3. Seamless scalability: It offers high automation and excellent reproducibility when integrated with standard chromatography systems. 

Weaknesses

1. Low mass transfer efficiency & low linear flow rate: The mass transfer rate is limited by diffusion, and the linear flow rate is constrained by column compressibility and pressure drop 
2. High equipment & media cost: The process requires specialized chromatography equipment and high-binding-capacity resins, which significantly increases both capital investment and consumable expenses. 
3. Complex process development: Optimization of binding and elution conditions, specifically pH and conductivity, is essential to balance purity, yield, and IgG subclass distribution. This adds substantial time and resource demands during process development and tech transfer. 

Heparin Affinity Chromatography

Principle 

This method exploits the specific affinity between the catalytic domain of FXIa and immobilized heparin, allowing for the selective capture of FXIa. 

Strengths 

1. High specificity: It delivers excellent purification performance by directly targeting the FXIa molecule, particularly effective for removing trace-level residual FXIa. 
2. Mild conditions: The process typically runs under physiological pH, ionic strength, and temperature, which helps preserve the structure and biological activity of IgG. 
3. Orthogonal mechanism: It captures FXIa that leaks through prior steps, complementary to hydrophobic- and charge-based methods such as caprylic acid precipitation. 

Weaknesses 

1. High cost: Heparin affinity resins are significantly more expensive, limiting their economic feasibility for large-scale manufacturing. 
2. Ligand leaching risk 
3. Low throughput: It is typically used as a polishing step with limited processing volume and is not suitable for large-scale capture from crude feed. 

Based on the above, Cobetter introduces a customized Viruclear™ prefilter. Built on the existing Viruclear™ PDS prefilter for virus clearance and integrating Pultrix™ S for membrane chromatography, it enables effective FXIa removal during the prefiltration stage. Even with the introduction of cationic membrane, a short-duration overloading strategy ensures both FXIa removal efficiency and protein yield. 

Viruclear™ Prefilters with Multiple Composite Layers 

Performance Comparison of Pultrix™ S Membrane 

Material Info 

Filter Info 

Process Parameters 

Results 

Experimental results show: 

1. The Viruclear™ PDS prefilter already demonstrates a baseline capacity for FXIa removal, even without the S membrane composite. As additional layers of S membrane are incorporated, FXIa removal performance improves proportionally; however, protein recovery declines accordingly. A balanced performance is achieved when the prefilter is composited with two layers of S membrane, offering high FXIa removal while maintaining relatively high protein recovery. 
2. Regarding scale-up, the two-layer composite configuration exhibits strong linear scalability. Both filtration metrics, such as loading capacity and average flux, and product quality attributes, including FXIa removal rate and protein recovery, remain consistent across scales. 

Based on the above experimental data, Cobetter introduces the Viruclear™ PDX cassettes for virus-removal prefiltration. 

Structure & Material 

Procurement Info

The Viruclear™ PDX prefilter enables effective FXIa removal directly at the virus-removal prefiltration stage. Its key advantages can be summarized in three areas: 

Significant cost-effectiveness:

No need to additionally configure expensive chromatography equipment and media. In commercial production, it can significantly shorten changeover cycles and reduce costs. 

Highly simplified process flow: 

No need to develop a dedicated FXIa removal step. Operation is straightforward, target removal is achieved in a single step. Furthermore, even with the introduction of a cationic membrane, a short-duration overloading strategy ensures both removal efficiency and product yield. 

Robust and easy to scale up: 

The prefilter integrates naturally with viral clearance, adapts to various production conditions, and delivers consistent inter-batch performance.